Drugs and patents in ATC class L01XD - Sensitizers used in photodynamic/radiation therapy

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
PHOTOFRIN	porfimer sodium
METVIXIA	methyl aminolevulinate hydrochloride
GLEOLAN	aminolevulinic acid hydrochloride
AMELUZ	aminolevulinic acid hydrochloride
LEVULAN	aminolevulinic acid hydrochloride
>Tradename	>Generic Name

Last updated: June 12, 2026

ATC L01XD Sensitizers in Photodynamic and Radiation Therapy: Market Dynamics and Patent Landscape

ATC class L01XD (“Sensitizers used in photodynamic/radiation therapy”) covers photo-activatable and/or radio-sensitizing agents used to potentiate tumor killing under light or ionizing radiation. The market is dominated by patented drug molecules, delivery formats (thermal control, liposomes/nanoparticles, conjugates), and treatment-specific method-of-use IP. Patent estates often separate into (1) active pharmaceutical ingredient (API) composition, (2) formulation and delivery systems, and (3) dosing and use claims tied to imaging-guided light dosimetry or fractionation/radiation scheduling. Revenue risk for branded products concentrates at the end of core composition patents, while regulatory exclusivity (where applicable) extends delay for generic entry.

This analysis maps the patent landscape and key market dynamics at a class level for L01XD sensitizers, then highlights the dominant IP “cliffs” and the entry paths that generics/biosimilars (small-molecule generics only) face.

Which companies lead the ATC L01XD sensitizers market and what drives demand?

Class L01XD demand is pulled by three forces: expansion of photodynamic therapy (PDT) indications and light-based oncology workflows, adoption of combination regimens with external beam radiation, and differentiation through delivery systems that improve tumor selectivity and reduce skin toxicity.

Demand drivers by therapy modality

Photodynamic therapy (PDT)
Growth is tied to office-based or outpatient procedures, longer-term adoption in dermatology and oncology, and integration with imaging for light dosimetry. Differentiation clusters around photosensitizer formulations that increase tumor accumulation and reduce phototoxicity.
Radiation sensitization (radio-sensitizers used with ionizing radiation)
Market pull comes from solid tumor radiation practices, new fractionation schemes, and the development of agents that alter tumor oxygenation or DNA damage response.
Combination regimens and sequence dependence
IP and clinical practice often treat PDT or radiation sensitization as protocol-driven. That amplifies method-of-use patent value and increases manufacturing and regulatory scrutiny for combination labeling.

Competitive intensity: where patents matter most

In L01XD, the main barriers to direct competition are not only API patents but also:

Formulation patents that protect encapsulation, particle size distributions, excipients, surface chemistry, and release profiles.
Light dosimetry and treatment scheduling patents that define effective irradiation parameters and timing of sensitizer administration.
Combination protocol patents (drug plus radiation conditions).

What patents protect ATC L01XD sensitizers used in photodynamic therapy (PDT)?

Class-level protection typically splits across composition, formulation/delivery, and method-of-use claims.

1) Composition of matter: the IP core

Patent claim sets usually cover:

The sensitizer chemical entity or salt forms.
Intermediate compounds and synthetic routes.
Polymorphs or amorphous forms (where relevant).
Stable derivatives that address aggregation or photobleaching.

2) Formulation and delivery systems: the differentiation layer

Frequent claim themes include:

Liposomes or lipid nanoparticles for improved biodistribution.
Conjugates (e.g., tumor-targeting ligands).
Nanocarriers controlling intracellular uptake and localization.
Controlled release matrices and excipient-defined compositions.

3) Method of use: protocols that sustain exclusivity

Method-of-use claims often include:

Patient selection criteria tied to tumor type/stage.
Administration time relative to light exposure or radiation delivery.
Irradiation wavelength, energy fluence, spot size, and schedule.
Protection measures for reducing photosensitivity-related adverse events.

Key implication for market entry

A generic manufacturer can sometimes clear composition patents but still face:

formulation infringement risk if dosage form matches the protected delivery system.
induced infringement risk if prescribing information or clinical protocol tracks the patented method.
design-around complexity because PDT parameters are not interchangeable.

Which patents protect ATC L01XD sensitizers used as radiation sensitizers?

Radiation sensitization IP trends toward biologically grounded use claims and dosing/timing.

Common patent categories

Composition and salts of the sensitizer.
Formulation for systemic delivery with minimal toxicity.
Method of use tied to:
- radiation dose and fractionation,
- co-administration timing,
- target oxygenation pathways,
- biomarkers or tumor phenotypes defining responsive patients.

Litigation-prone claim scope

Radiation sensitizer cases often hinge on:

the claimed “effective range” of irradiation parameters,
whether combinations are required for claimed efficacy,
the specificity of timing (e.g., hours/days prior to irradiation).

When does patent exclusivity for L01XD sensitizers expire and what are the typical “IP cliff” timelines?

At class level, exclusivity timelines follow a two-layer pattern:

Primary composition patents expire first (around 20 years from earliest non-provisional filing, subject to term adjustments and patent term extensions).
Formulation and method-of-use patents can remain enforceable after composition expiry, especially if filed later as improvements.

Typical timeline structure (class-level)

Earliest filing → ~6–10 years to launch (varies by development time and regulatory path).
Core composition patent expiry: often the first major cliff for direct small-molecule generics.
Later-filed formulation/method patents: can create a second wave of barriers.

Regulatory exclusivity overlay

For drugs approved via FDA pathways (if applicable by molecule), exclusivity can extend market protection even after some patents expire:

non-patent exclusivity (drug-device combos or data exclusivity where applicable),
pediatric exclusivity,
orphan drug exclusivity (where relevant to specific sensitizer products and indications).

Practical impact for generic entry

Market entry timing is usually determined by:

the last enforceable “blocking” patent among composition, formulation, and method-of-use,
whether a generic can offer a design-around that avoids infringement while meeting labeling requirements.

How many patents cover each L01XD sensitizer product and what is the estate strength?

Class-level estate breadth is high because PDT/radiation protocols are multi-parameter. Typical estates in this class include multiple overlapping patents covering:

core molecule,
salts/polymorphs,
delivery system,
manufacturing process,
method-of-use and dosing,
combination protocols with light or radiation.

What “strong estate” looks like in this class

multiple independent claim groups in the same family (composition plus formulation plus use),
continuation filings that keep patent coverage alive across protocol improvements,
jurisdictional coverage in major markets (US, EP, JP, CN) for high-value products,
at least one late-expiring patent related to formulation or dosimetry.

What is the Orange Book status of L01XD sensitizers and where are Paragraph IV challenges likely?

For ATC L01XD, generic entry is only possible for products with:

FDA-approved small-molecule sensitizers,
an applicable reference listed drug (RLD),
Orange Book-listed patents that cover the referenced product.

Paragraph IV filings are likely where:

core composition patents have expired or are close to expiry,
there is no effective “formulation blocking” patent,
generics can support ANDA bioequivalence without matching the protected delivery design.

Entry risks that reduce Paragraph IV frequency

Many PDT sensitizers are protected by delivery-system patents that generics cannot easily replicate without infringement.
Method-of-use claims are harder to carve out via labeling, depending on how prescribing information reflects patented protocols.
Multi-parameter irradiation and timing protocols increase the chance that “label use” aligns with claimed methods.

Which generic entry risks exist for L01XD sensitizers after composition patent expiry?

Even when composition patents expire, entry risk remains elevated.

1) Formulation and delivery system non-equivalence

Generics may be blocked by:

specific excipient systems or encapsulation technologies,
particle size range and surface properties,
release kinetics profiles tied to tumor uptake.

2) Labeling and method-of-use alignment

If the generic label includes:

the same timing and dosing relative to irradiation,
the same wavelength or energy parameters, then method-of-use claims can remain a barrier.

3) Clinical protocol substitution friction

Clinicians often follow standard light dosimetry and administration timing. If standard of care matches patented parameters, generics face higher infringement exposure under “induced” theories in some jurisdictions.

What patent litigation affects L01XD sensitizers and how does it shape settlement behavior?

At class level, litigation patterns tend to involve:

enforcement of late-expiring formulation/use patents,
pressure to enter under license or consent judgment,
settlement terms that delay entry until a defined date or until a “carved-out” product is launched.

Settlement behaviors that recur

Staggered launch dates aligned with the expiry of the last blocking patent.
Design-around concessions: changes to formulation or labeling language.
Channel restrictions: sometimes tied to hospital administration practices for PDT/radiation workflows.

How do patent estates for PDT sensitizers compare with radiation sensitizers in L01XD?

PDT sensitizer IP tends to emphasize:

wavelength/fluence and timing relative to light,
delivery systems for phototoxicity control,
treatment workflow integration.

Radiation sensitizer IP tends to emphasize:

fractionation schemes,
oxygenation pathway modulation,
biomarker-driven patient selection.

Comparative consequence for market entry

PDT generics face higher barriers if the protocol is tightly linked to patented dosimetry and light parameters.
Radiation sensitizer generics face higher barriers where combination regimens are essential and where timing plus fractionation falls into the claimed ranges.

What formulations are protected by patents for L01XD sensitizers (liposomes, nanoparticles, conjugates)?

Patent protection commonly covers specific formulation classes:

Liposomes and lipid-based carriers
Claims often target lipid composition, encapsulation efficiency, size range, and stability under storage.
Nanoparticles and polymeric carriers
Claims often target surface modifications, ligand density, zeta potential range, and release profile.
Conjugates
Claims often target linker chemistry, drug-to-target ratio, and stability for in vivo circulation.

Why formulation patents matter commercially

Formulation can determine:

tumor selectivity and retention,
skin phototoxicity thresholds,
operational compatibility with clinical protocols (dose prep, administration route, infusion time).

What method-of-use and dosing patents most often block generics for L01XD sensitizers?

Method-of-use and dosing patents block generic entry when:

dosing schedules are explicitly defined (time windows).
irradiation/radiation parameters are defined (wavelength, fluence, fractionation).
patient selection criteria create a conditional claim.

Claim design that increases enforcement leverage

Independent claims with protocol ranges that cover “typical clinical practice,” not only a narrow experimental parameter set.
Dependent claims linking administration timing and dosimetry to observed efficacy endpoints.

Which jurisdictions carry the strongest patent risk for L01XD sensitizer products?

High-stakes markets for enforcement typically include:

US: Orange Book listings, Hatch-Waxman litigation leverage, method-of-use and formulation claims in district court.
EP: validation breadth and injunctive potential for granted patents.
CN: enforcement momentum and local litigation mechanisms.
JP: patent system and pharmaceutical enforcement cadence.

For high-value PDT/radiation sensitizers, commercial risk concentrates where both:

the patent is granted, and
enforcement history and litigation infrastructure supports action.

Key product-level patent mapping: which L01XD sensitizer drugs drive the estate complexity?

A complete product-by-product patent map requires each marketed drug’s molecule and FDA/EMA/NMPA identifier, plus the full patent family and jurisdiction set. The class-level dynamics described above explain why the landscape is crowded and why late-expiring formulation and protocol patents extend exclusivity for L01XD sensitizers in both photodynamic and radiation sensitization contexts.

Key Takeaways

L01XD sensitizers are protected through layered IP: composition, formulation/delivery, and method-of-use tied to irradiation or radiation parameters.
Market exclusivity is typically extended by later-filed formulation and protocol patents even after core API patents expire.
Generic entry risk is high because PDT and radiation sensitization are protocol-driven, making “label use” and delivery-system equivalence central infringement vectors.
Orange Book and Paragraph IV challenges are most feasible when composition patents are near expiry and formulation/protocol patents do not create a blocking estate.
Litigation and settlements in this class tend to delay entry via late-expiring formulation/use patents and design-around constraints.

FAQs

1) What types of PDT light parameters are usually locked by L01XD sensitizer patents?

Patents frequently define wavelength band, energy fluence or dose rate, treatment duration, and timing between sensitizer administration and light exposure.

2) Do L01XD sensitizer generics need to match the same delivery system to avoid infringement?

Often yes. Formulation and delivery-system patents in this class can create infringement risk even if the API is off-patent.

3) How do dosing timing claims affect generic labeling for L01XD sensitizers?

If labels include timing windows and irradiation/radiation conditions that mirror patented protocols, method-of-use risk increases and can deter or delay ANDA launches.

4) Are combination regimens with radiation more patent-restrictive than PDT monotherapy?

Radiation sensitization IP often centers on fractionation and scheduling, while PDT centers on light dosimetry and phototoxicity control. Both can be restrictive when claim scope tracks standard clinical workflows.

5) Which patent families are usually the last to expire for L01XD sensitizers?

Late-expiring families commonly cover formulation improvements, delivery technologies, and protocol-specific method-of-use claims rather than the first-generation composition.

References (APA)

World Health Organization. (n.d.). ATC classification database: L01XD. WHO.
FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
European Patent Office. (n.d.). Espacenet patent search. European Patent Office.
FDA. (n.d.). Hatch-Waxman Drug Patent Litigation and the Orange Book. U.S. Food and Drug Administration.